Next-Generation Oncolytic Virus System for Enhanced Cancer Treatment

A revolutionary oncolytic virus system that leverages advanced enzyme engineering, personalized medicine, and cutting-edge diagnostics to selectively target and destroy cancer cells, offering a paradigm shift in cancer treatment.

Despite the progress made in oncolytic virus research, existing therapies still face limitations in terms of safety, efficacy, and tumor selectivity. The original patent's oncolytic virus, although improved, still relies on a traditional HSV-TK enzyme and lacks personalized targeting capabilities. The new inventive concept addresses these limitations by introducing a next-generation oncolytic virus system that combines advanced enzyme engineering, personalized medicine, and cutting-edge diagnostics.

The new inventive concept comprises a recombinant oncolytic virus vector that encodes a chimeric HSV-TK enzyme with enhanced substrate specificity for a prodrug, allowing for selective targeting and destruction of cancer cells. The system also includes a method for administering the prodrug to a patient in need thereof. Additionally, the inventive concept encompasses methods for treating cancer using truncated HSV-TK enzyme variants with improved thermal stability, and for detecting cancer cells using radiolabeled prodrugs. Furthermore, the system enables personalized cancer therapy by identifying patient-specific prodrugs based on genetic profiles.

The new claims introduce a paradigm shift in oncolytic virus research by combining advanced enzyme engineering, personalized medicine, and cutting-edge diagnostics. The use of chimeric HSV-TK enzymes, truncated HSV-TK enzyme variants, and radiolabeled prodrugs represents a significant departure from the traditional HSV-TK enzyme used in the original patent. The inventive concept's focus on personalized cancer therapy and advanced diagnostics also sets it apart from existing oncolytic virus therapies.

Alternative embodiments of the inventive concept could include the use of different viral vectors, such as adenovirus or lentivirus, or the development of novel prodrugs with improved pharmacokinetics. Variations of the system could also include the integration of artificial intelligence or machine learning algorithms to optimize personalized cancer therapy.

The next-generation oncolytic virus system has the potential to revolutionize the cancer treatment market, offering a safer, more effective, and personalized approach to cancer therapy. The market for oncolytic virus therapies is expected to grow significantly in the coming years, driven by increasing demand for innovative cancer treatments. The inventive concept's focus on personalized medicine and advanced diagnostics also positions it for success in the rapidly growing precision medicine market.